6533b7d8fe1ef96bd126a521
RESEARCH PRODUCT
Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease
Maria Rosa RizzutoMario CottoneSara RennaFilippo MocciaroAmbrogio Orlandosubject
education.field_of_studyCrohn's diseasemedicine.medical_specialtySettore MED/09 - Medicina Internaintegumentary systembusiness.industryPopulationMucocutaneous zoneoral lichen planu certolizumab crohnGastroenterologyGeneral Medicinemedicine.diseaseDermatologyPathogenesisstomatognathic diseasesBasal (phylogenetics)medicineOral lichen planusCertolizumab pegoleducationbusinessCD8medicine.drugdescription
Dear Sir , Lichen planus (LP) is a relatively uncommon inflammatory dermatosis of the mucocutaneous surfaces that can present with a variety of clinical manifestations and, most commonly, affecting middle-aged adults. The disease course may be short or chronic, although most cases may resolve after 1 month to 7 years. The real prevalence of LP is unknown, but is estimated to be 1% in the USA.1 The pathogenesis of LP is not entirely understood. In general, activated T lymphocytes are recruited to the dermal–epidermal junction and induce apoptosis in basal keratinocytes. Both CD4+ and CD8+ T lymphocytes are found in the lichenoid infiltrate of LP, with a predominance of the latter cell type being present in established lesions.1 Ten to 20% of patients with LP demonstrate both oral and cutaneous lesions. Oral lichen planus (OLP) manifestations occur in approximately 2% of the general population, while cutaneous lesions occur in 0.4%. We report a rare …
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-04-01 | Journal of Crohn's and Colitis |